FDA Guidance and Notices, August 2026: Revised Human Factors Guidance and a Discussion Paper on Generative AI Devices
The main final guidance of August 2026 is the August 3 revision of FDA's guidance on applying human factors and usability engineering to medical devices, which pairs naturally with May's guidance on human factors information in marketing submissions. On August 18, FDA released a discussion paper on regulating generative AI-enabled medical devices, covering risk assessment, premarket evaluation and postmarket monitoring, and is taking feedback until October 19. The paper is not guidance and does not settle FDA's expectations.
In the Federal Register, FDA proposed a list of accessories that could be placed in class I separately from the devices they are used with; comments are due October 16. The classification rules include proposals to reclassify digital breast tomosynthesis systems and cystoscope systems that help detect bladder cancer.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles